4-(2-{[4-{[3-(4-Chlorophenyl)Propyl]Sulfanyl}-6-(1-Piperazinyl)-1,3,5-Triazin-2-Yl]Amino}Ethyl)Phenol

Identification

Name
4-(2-{[4-{[3-(4-Chlorophenyl)Propyl]Sulfanyl}-6-(1-Piperazinyl)-1,3,5-Triazin-2-Yl]Amino}Ethyl)Phenol
Accession Number
DB04020  (EXPT02212)
Type
Small Molecule
Groups
Experimental
Description
Not Available
Structure
Thumb
Synonyms
Not Available
Categories
Not Available
UNII
Not Available
CAS number
Not Available
Weight
Average: 485.045
Monoisotopic: 484.181207977
Chemical Formula
C24H29ClN6OS
InChI Key
AIBKIFHSQQYXLG-UHFFFAOYSA-N
InChI
InChI=1S/C24H29ClN6OS/c25-20-7-3-18(4-8-20)2-1-17-33-24-29-22(27-12-11-19-5-9-21(32)10-6-19)28-23(30-24)31-15-13-26-14-16-31/h3-10,26,32H,1-2,11-17H2,(H,27,28,29,30)
IUPAC Name
4-{2-[(4-{[3-(4-chlorophenyl)propyl]sulfanyl}-6-(piperazin-1-yl)-1,3,5-triazin-2-yl)amino]ethyl}phenol
SMILES
OC1=CC=C(CCNC2=NC(SCCCC3=CC=C(Cl)C=C3)=NC(=N2)N2CCNCC2)C=C1

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UEstrogen receptor betaNot AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
9957008
PubChem Substance
46505687
ChemSpider
8132617
BindingDB
50121626
ChEMBL
CHEMBL346455
HET
MON
PDB Entries
1nde

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00471 mg/mLALOGPS
logP4.83ALOGPS
logP6.04ChemAxon
logS-5ALOGPS
pKa (Strongest Acidic)10.26ChemAxon
pKa (Strongest Basic)8.66ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area86.2 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity140.67 m3·mol-1ChemAxon
Polarizability53.4 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.924
Blood Brain Barrier+0.6337
Caco-2 permeable-0.5917
P-glycoprotein substrateSubstrate0.6831
P-glycoprotein inhibitor INon-inhibitor0.652
P-glycoprotein inhibitor IIInhibitor0.7543
Renal organic cation transporterInhibitor0.6421
CYP450 2C9 substrateNon-substrate0.8107
CYP450 2D6 substrateNon-substrate0.718
CYP450 3A4 substrateNon-substrate0.6358
CYP450 1A2 substrateInhibitor0.8108
CYP450 2C9 inhibitorNon-inhibitor0.5626
CYP450 2D6 inhibitorNon-inhibitor0.6696
CYP450 2C19 inhibitorNon-inhibitor0.6587
CYP450 3A4 inhibitorInhibitor0.633
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8683
Ames testNon AMES toxic0.6268
CarcinogenicityNon-carcinogens0.8425
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.5129 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.6821
hERG inhibition (predictor II)Inhibitor0.724
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as n-arylpiperazines. These are organic compounds containing a piperazine ring where the nitrogen ring atom carries an aryl group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazinanes
Sub Class
Piperazines
Direct Parent
N-arylpiperazines
Alternative Parents
1,3,5-triazine-2,4-diamines / Alkyl-2-thio-S-triazines / Dialkylarylamines / Secondary alkylarylamines / 1-hydroxy-2-unsubstituted benzenoids / Alkylarylthioethers / N-aliphatic s-triazines / Chlorobenzenes / Aryl chlorides / Heteroaromatic compounds
show 7 more
Substituents
N-arylpiperazine / 2,4-diamine-s-triazine / Dialkylarylamine / Alkyl-2-thio-s-triazine / Aryl thioether / Secondary aliphatic/aromatic amine / Phenol / Halobenzene / N-aliphatic s-triazine / Chlorobenzene
show 27 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Targets

Details
1. Estrogen receptor beta
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
Nuclear hormone receptor. Binds estrogens with an affinity similar to that of ESR1, and activates expression of reporter genes containing estrogen response elements (ERE) in an estrogen-dependent m...
Gene Name
ESR2
Uniprot ID
Q92731
Uniprot Name
Estrogen receptor beta
Molecular Weight
59215.765 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]

Drug created on June 13, 2005 07:24 / Updated on December 01, 2017 15:22